These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10389653)

  • 101. Pharmacodynamics of (-)-beta-2',3'-dideoxy-3'-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans.
    Hurwitz SJ; Tennant BC; Korba BE; Gerin JL; Schinazi RF
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2804-9. PubMed ID: 9797207
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Doctor-to-patient transmission of viral hepatitis B: is it a problem, is there a solution?
    Schalm SW; van Wijngaarden JK
    J Viral Hepat; 2000 Jul; 7(4):245-9. PubMed ID: 10886532
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Antiviral effect of Chinese medicine jiaweisinisan in hepatitis B virus transgenic mice.
    Chen XY; Tong GD; Xia F
    World J Gastroenterol; 2006 Apr; 12(14):2280-3. PubMed ID: 16610037
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Is HBV RNA a valid marker for predicting sustained viral response for nucleoside analogue cessation?
    Meena BL; Premkumar M; Roy A; Singh V
    Gut; 2021 Oct; 70(10):2008-2009. PubMed ID: 33158981
    [No Abstract]   [Full Text] [Related]  

  • 105. Treatment of subacute hepatitis with Lamivudine and intravenous Glycyrrhizin: a pilot study.
    Tandon A; Tandon BN; Bhujwala RA
    Hepatol Res; 2001 May; 20(1):1-8. PubMed ID: 11282481
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Breaking B and T cell tolerance using cationic lipid--DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV.
    Morrey JD; Motter NE; Chang S; Fairman J
    Antiviral Res; 2011 Jun; 90(3):227-30. PubMed ID: 21545812
    [TBL] [Abstract][Full Text] [Related]  

  • 107. The Anti-hepatitis B Virus Activity of Boehmeria nivea Extract in HBV-viremia SCID Mice.
    Chang JM; Huang KL; Yuan TT; Lai YK; Hung LM
    Evid Based Complement Alternat Med; 2010 Jun; 7(2):189-95. PubMed ID: 18955304
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Efficacy of cationic lipid-DNA complexes (CLDC) on hepatitis B virus in transgenic mice.
    Morrey JD; Motter NE; Taro B; Lay M; Fairman J
    Antiviral Res; 2008 Jul; 79(1):71-9. PubMed ID: 18358544
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model.
    Iyer RP; Roland A; Jin Y; Mounir S; Korba B; Julander JG; Morrey JD
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2318-20. PubMed ID: 15155244
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Distribution and anti-HBV effects of antisense oligodeoxynucleotides conjugated to galactosylated poly-L-lysine.
    Zheng SJ; Zhong S; Zhang JJ; Chen F; Ren H; Deng CL
    World J Gastroenterol; 2003 Jun; 9(6):1251-5. PubMed ID: 12800234
    [TBL] [Abstract][Full Text] [Related]  

  • 111. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
    Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
    Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature.
    Ben-Ari Z; Mor E; Tur-Kaspa R
    J Intern Med; 2003 May; 253(5):544-52. PubMed ID: 12702032
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine.
    Morrey JD; Bailey KW; Korba BE; Sidwell RW
    Antiviral Res; 1999 Jun; 42(2):97-108. PubMed ID: 10389653
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Transgenic mice as a chemotherapeutic model for hepatitis B virus infection.
    Morrey JD; Korba BE; Sidwell RW
    Antivir Ther; 1998; 3(Suppl 3):59-68. PubMed ID: 10726056
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Evaluation of anti-hepatitis B virus (HBV) drugs using the HBV transgenic mouse: application of the semiquantitative polymerase chain reaction (PCR) for serum HBV DNA to monitor the drug efficacy.
    Kajino K; Kamiya N; Yuasa S; Takahara T; Sakurai J; Yamamura Ki; Hino O
    Biochem Biophys Res Commun; 1997 Dec; 241(1):43-8. PubMed ID: 9405231
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Preliminary study on the efficacy and safety of lamivudine and interferon alpha therapy in decreasing serum HBV DNA level in HBV positive transgenic mice during pregnancy.
    Li D; Xu DZ; Choi BC; Men K; Zhang JX; Lei XY; Yan YP
    J Med Virol; 2005 Jun; 76(2):203-7. PubMed ID: 15834875
    [TBL] [Abstract][Full Text] [Related]  

  • 117.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 118.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.